Listen on the go
CORRECT!
Next question
touchONCOLOGY touchONCOLOGY
Prostate Cancer
Watch Time: 7 mins

Arnulf Stenzl: Highlights from EAU23!

Copy Link
Published Online: May 25th 2023

touchONCOLOGY caught up with the Secretary General of the European Association of Urology (EAU), Prof Arnulf Stenzl, to discuss some of the key advances from the conference. He focusses this interview on prostate cancer, early detection, systemic therapy, new therapies in castration-resistant prostate cancer and the latest knowledge in the use of PARP inhibitors.

Topics covered

  • Improving early detection of prostate cancer, postate specific antigen and new imaging techniques (00:20)
  • Developments in systemic therapy of early, hormone sensitive metastatic prostate cancer, including the ARCHES trial data (3:30)
  • New therapies for castration-resistant prostate cancer (5:45)
  • Latest advances and knowledge of PARP inhibitors (6:45)

Disclosures: Arnulf Stenzl has nothing to disclose in relation to this video interview.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.

Filmed as a highlight of EAU23

Access more content on genitourinary cancers here 

 

Share this Video
Related Videos In Prostate Cancer
Prostate Cancer
Developed by Touch
ARPi vs. SOC and taxanes in mCRPC – ProBio study: Henrik Grönberg, EMSO 2023
Watch Time: 7 mins

The uniquely designed Prostate Biomarker (ProBio) study (NCT03903835) used outcome-adaptive randomization to compare biomarker-driven treatment selection against physician’s choice, and to compare androgen receptor inhibitors (ARPIs) against standard-of-care (SOC) and taxanes in castrate-resistant prostate cancer (mCRPC). To learn more about the trials unique design, the details surrounding the biomarker signatures investigated and the treatments compared, […]

Prostate Cancer
Developed by Touch
Arnulf Stenzl: Highlights from EAU23!
Watch Time: 7 mins

touchONCOLOGY caught up with the Secretary General of the European Association of Urology (EAU), Prof Arnulf Stenzl, to discuss some of the key advances from the conference. He focusses this interview on prostate cancer, early detection, systemic therapy, new therapies in castration-resistant prostate cancer and the latest knowledge in the use of PARP inhibitors. Topics […]

Genitourinary Cancer, Prostate Cancer
Axel Merseburger: Current advances in prostate cancer treatment options and what we might expect in the next 5 years
Watch Time: 3 mins

Our Editor-in-Chief Axel Merseburger (Lübeck University, Lübeck, Germany) discusses the most important recent advances in the treatment landscape for prostate cancer, including screening using MRI and PSMA PET-CT scans, and triplet therapies using hormone therapy and PARP inhibitors. He also takes a look to the future, discussing developments he hopes to see in early detection, […]

Trending In Prostate Cancer:

ARPi vs. SOC and taxanes in mCRPC – ProBio study: Henrik Grönberg, EMSO 2023
Prostate Cancer
    • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72